<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856853</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F647-1701</org_study_id>
    <nct_id>NCT03856853</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GNI-EPS Pharmaceuticals, Inc. (GNI Group)</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects&#xD;
      with systemic sclerosis-associated interstitial lung disease (SSc-ILD)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">May 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change from baseline (%) of FVC%</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pirfenidone group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>pirfenidone for SSc-ILD treatment</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>as control</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Female or male subjects aged between 18 and 75 years of age. 2.2013 ACR / EULAR&#xD;
        classification criteria for SSc fulfilled. 3.SSc disease onset (defined by first&#xD;
        non-Raynaud symptom) within 5 years. 4.SSc related Interstitial Lung Disease confirmed by&#xD;
        HRCT. 5.Forced vital capacity (FVC) 40% to 70% predicted(include 40% and70% ). 6.Subject&#xD;
        have the ability to understand and sign the informed consent before the trials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects not fulfill all of the above inclusion criteria.&#xD;
&#xD;
          2. AST, ALT &gt;1.5 x ULN.&#xD;
&#xD;
          3. Bilirubin &gt;1.5 x ULN.&#xD;
&#xD;
          4. Creatinine clearance &lt;30 mL/min.&#xD;
&#xD;
          5. Airway obstruction (pre-bronchodilator FEV1/FVC &lt;0.7).&#xD;
&#xD;
          6. Other clinically significant pulmonary abnormalities.&#xD;
&#xD;
          7. Allergic to test drugs or components (e.g. lactose).&#xD;
&#xD;
          8. Clinical Significant Pulmonary hypertension:.&#xD;
&#xD;
               1. Significant past clinical evidence or echocardiography of right heart failure.&#xD;
&#xD;
               2. History of right heart catheterization showed that cardiac index ≤ 2 l/min/m2.&#xD;
&#xD;
               3. Pulmonary hypertension, which needs to use EPoprostenol/ Treprostinil for&#xD;
                  parenteral treatment .&#xD;
&#xD;
          9. Cardiovascular diseases:&#xD;
&#xD;
               1. Six weeks in severe hypertension, and out of control after&#xD;
                  treatment(≥160/100mmHg).&#xD;
&#xD;
               2. Myocardial infarction within six months.&#xD;
&#xD;
               3. A period of 6 months in unstable angina.&#xD;
&#xD;
         10. More than 3 digital fingertip ulcers or a history of severe digital necrosis requiring&#xD;
             hospitalization or severe other ulcers.&#xD;
&#xD;
         11. Bleeding risk, including the following criterias:&#xD;
&#xD;
             a. Predisposition to bleeding. b.Subjects need to the following treatments:&#xD;
             i.Fibrinolysis, full-dose anticoagulation therapy(such as vitamin K antagonists,&#xD;
             direct thrombin inhibitor, heparin, Hirudin ).&#xD;
&#xD;
             ii. High dose antiplatelet therapy[Note: not prohibited to maintain equipment needed&#xD;
             indwelling venous pathway prophylactic low dose of heparin or heparin fluid (e.g.&#xD;
             enoxaparin, daily 4000 I.U. s.c.) and the prevention of the use of antiplatelet&#xD;
             therapy (e.g. acetylsalicylic acid, until 325 mg/d, or other antiplatelet dose of 75&#xD;
             mg/d the same dose of clopidogrel, or treatment)].&#xD;
&#xD;
             c.history of hemorrhagic central nervous system (CNS) event within last year. d. Any&#xD;
             of the following conditions within 3 months: i.Hemoptysis or hematuria ii. Active&#xD;
             gastrointestinal bleeding or gastrointestinal ulcer. iii. major trauma or major&#xD;
             surgery (researchers determined). e.coagulation parameters:international normalised&#xD;
             ratio (INR) &gt;2, prolongation of prothrombin time (PT) and partial thromboplastin time&#xD;
             (PTT) by &gt;1.5 x ULN)&#xD;
&#xD;
         12. May interfere with detection procedures (such as interrupt oxygen intolerance in&#xD;
             pulmonary function tests) or based on the researchers estimate, may affect the test to&#xD;
             participate in or participate in the test may put patients at risk of disease or other&#xD;
             complications (such as caused by SSc severe gastrointestinal symptoms).&#xD;
&#xD;
         13. Researchers determined that life expectancy was due to other diseases (non SSc) for a&#xD;
             period of up to 2.5 years.&#xD;
&#xD;
         14. Clinical signs of malabsorption or needing parenteral nutrition.&#xD;
&#xD;
         15. History of thrombotic event within last year(Including stroke and transient ischemic&#xD;
             attack).&#xD;
&#xD;
         16. Previous treatment with nintedanib or pirfenidone.&#xD;
&#xD;
         17. Use the following medicine:&#xD;
&#xD;
               1. Treatment with prednisone &gt;10 mg/day within 2 weeks.&#xD;
&#xD;
               2. Treatment with azathioprine, hydroxychloroquine, colchizine, D-penicillamine,&#xD;
                  sulfasalazine within 8 weeks .&#xD;
&#xD;
               3. Treatment with cyclophosphamide, rituximab, tocilizumab, abatacept, leflunomide,&#xD;
                  tacrolimus, newer anti-arthritic treatments like tofacitinib and ciclosporine A,&#xD;
                  potassium para-aminobenzoate within 6 months.&#xD;
&#xD;
         18. Unstable background therapy with cyclophosphamide or mycophenolate mofetil / sodium or&#xD;
             methotrexate (not allow treatment). Patients must or A. patients cannot receive&#xD;
             immunosuppressive therapy, sodium cyclophosphamide or mycophenolate mofetil / or MTX&#xD;
             stable or B. within 6 months of acceptance, and in at least 6 months after&#xD;
             randomization, the treatment to keep the background stable (exclusion criteria 16 and&#xD;
             17 and the combined use of early precautions).&#xD;
&#xD;
         19. Previous or planned hematopoietic stem cell transplantation next year.&#xD;
&#xD;
         20. Major surgery is planned during the treatment period.&#xD;
&#xD;
         21. Pregnancy or lactation or make a schedule during the trials.&#xD;
&#xD;
         22. Give the drug 28 days before or after administration of the 3 month period, women of&#xD;
             childbearing age * are unwilling or unable to use contraceptive methods highly&#xD;
             effective (according to ICH M3 (R2)), a highly effective means in the correct and&#xD;
             consistent application of a barrier method when the failure rate of less than 1% per&#xD;
             year. * women of childbearing age is defined has undergone menarche and in line with&#xD;
             &quot;infertile women&quot; standard &quot;[female infertile women&quot; is defined as: postmenopausal&#xD;
             period (12 months without menstruation, no other medical reasons) or permanent&#xD;
             sterilization (e.g., tubal occlusion, hysterectomy, bilateral ovarian resection or&#xD;
             bilateral tubal resection women)].&#xD;
&#xD;
        (23)According to the researchers,exhibited evidence of alcohol or drug abuse. (24)Patients&#xD;
        who were unable to understand or comply with the procedure were included in the&#xD;
        self-administered questionnaire, which was completed without help.&#xD;
&#xD;
        25.Patients with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment).&#xD;
&#xD;
        26.Clinical signs of malabsorption or needing parenteral nutrition. 27.With active peptic&#xD;
        ulcer. 28.With mental illness . 29.Within 3 months to participate in other clinical trials.&#xD;
        30.Researchers determined that they did not participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhang, Ling</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Zhang</last_name>
      <phone>+86-13501209210</phone>
      <email>rlzhang1006@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qian Wang</last_name>
      <phone>+86-13681211155</phone>
      <email>zhengaqian@icloud.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

